Package Leaflet: Information for the User
Fendrix Injectable Suspension
Hepatitis B vaccine (ADNr) (adjuvanted, adsorbed)
Read all of this leaflet carefully before you receive this vaccine because it contains important information for you.
Contents of the pack
Fendrix is a vaccine that prevents hepatitis B.
It is used in patients with kidney problems:
Fendrix is for adults and adolescents from 15 years of age.
What is hepatitis B
Hepatitis B is caused by a virus that makes the liver swell.
Hepatitis B carriers
How Fendrix works
Fendrix must not be administered
Fendrix must not be administered if any of the above applies to you. If you are not sure, consult your doctor or pharmacist before receiving Fendrix.
Warnings and precautions
Consult your doctor or pharmacist before Fendrix is administered to you:
Fainting (especially in adolescents) may occur before or after any injection, so you should tell your doctor or nurse if you have fainted after a previous injection.
If any of the above applies to you (or if you are not sure), consult your doctor or pharmacist before receiving Fendrix.
Other medicines and Fendrix
Tell your doctor if you are using, have recently used or might use any other medicines or if you have recently received any other vaccine.
Pregnancy, breastfeeding and fertility
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before receiving this vaccine.
Driving and using machines
You may feel tired or have a headache after receiving Fendrix. If this happens, be extra careful while driving or using tools or machines.
Fendrix contains sodium
This vaccine contains less than 1 mmol of sodium (23 mg) per dose, i.e. it is essentially “sodium-free”.
How the vaccine is administered
Your doctor or nurse will inject Fendrix into a muscle, usually in the upper part of your arm.
How much is administered
Your doctor will tell you if you need any additional injections or booster doses in the future. Fendrix can also be used as a booster dose after a course of vaccination with a different type of hepatitis B vaccine.
If you miss a dose
Like all medicines, this vaccine can cause side effects, although not everybody gets them.
The following side effects may occur with this vaccine. Their frequency is defined as follows:
Very common(these may occur with more than 1 in 10 doses of the vaccine): headache, feeling tired, pain or discomfort where the injection was given.
Common(these may occur with up to 1 in 10 doses of the vaccine): redness or swelling where the injection was given, fever, digestion and stomach problems.
Uncommon(these may occur with up to 1 in 100 doses of the vaccine): chills, skin rash with redness, other reactions where the injection was given.
Rare(these may occur with up to 1 in 1,000 doses of the vaccine): allergic reactions, flushing, feeling dizzy, feeling thirsty, feeling nervous, viral infection, back pain, tendon inflammation.
The following side effects have also been reported with other hepatitis B vaccines:
Very rare(these may occur with up to 1 in 10,000 doses of the vaccine): seizures, fainting, problems with the nerves of your eye (optic neuritis), multiple sclerosis, loss of sensation or problems moving some parts of your body, severe headache with stiff neck, numbness or weakness of arms and legs (neuropathy), nerve inflammation (neuritis), weakness and paralysis of the limbs progressing to the chest and face (Guillain-Barré syndrome), brain swelling or infection (encephalitis, encephalopathy).
Allergic reactions, including anaphylactoid reactions, may also occur very rarely (up to 1 in 10,000 doses of the vaccine). These can be local or widespread skin rashes with itching or blisters, swelling of the eyes and face, difficulty breathing or swallowing, sudden drop in blood pressure and loss of consciousness. These reactions can occur before you leave the doctor's surgery. However, seek medical attention immediately in any case.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if they are not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Agency's website for reporting adverse reactions, https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Fendrix composition
Hepatitis B virus surface antigen 1, 2, 3 20 micrograms
Adjuvanted by AS04C which contains:
3-O-desacil-4'-monophosphoryl lipid A (MPL) 50 micrograms
Adsorbed on aluminum phosphate (0.5 milligrams of Al3+ in total)
Produced by recombinant DNA technology in yeast cells (Saccharomyces cerevisiae)
Product appearance and container contents
Fendrix is a white and milky suspension.
Fendrix is available in a pre-filled syringe with or without separate needles, package sizes of 1 and 10.
Only some package sizes may be marketed.
Marketing authorization holder and manufacturer:
GlaxoSmithKline Biologicals s.a.
Rue de l’Institut 89
B-1330 Rixensart
Belgium
For further information on this medicinal product, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien GlaxoSmithKline Pharmaceuticals SA/NV Tel: + 32 10 85 52 00 | Lietuva GlaxoSmithKline Biologicals SA Tel: +370 80000334 |
България GlaxoSmithKline Biologicals SA Tel: + 359 80018205 | Luxembourg/Luxemburg GlaxoSmithKline Pharmaceuticals SA/NV Tel: + 32 10 85 52 00 |
Ceská republika GlaxoSmithKline s.r.o. Tel: + 420 2 22 00 11 11 cz.info@gsk.com | Magyarország GlaxoSmithKline Biologicals SA Tel: + 36 80088309 |
Danmark GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00 dk-info@gsk.com | Malta GlaxoSmithKline Biologicals SA Tel: + 356 80065004 |
Deutschland GlaxoSmithKline GmbH & Co. KG Tel: + 49 (0)89 360448701 produkt.info@gsk.com | Nederland GlaxoSmithKline BV Tel: + 31 (0)30 69 38 100 |
Eesti GlaxoSmithKline Biologicals SA Tel: +372 8002640 | Norge GlaxoSmithKline AS Tlf: + 47 22 70 20 00 |
Ελλάδα GlaxoSmithKline Μονοπρόσωπη A.E.B.E. Τηλ: + 30 210 68 82 100 | Österreich GlaxoSmithKline Pharma GmbH. Tel: + 43 (0)1 970 75-0 at.info@gsk.com |
España GlaxoSmithKline, S.A. Tel: + 34 900 202 700 es-ci@gsk.com | Polska GSK Services Sp. z o.o. Tel: + 48 (22) 576 9000 |
France Laboratoire GlaxoSmithKline Tél: + 33 (0) 1 39 17 84 44 diam@gsk.com Hrvatska GlaxoSmithKline Biologicals SA Tel: + 385 800787089 | Portugal Smith Kline & French Portuguesa - Produtos Farmacêuticos, Lda. Tel: + 351 21 412 95 00 FI.PT@gsk.com România GlaxoSmithKline Biologicals SA Tel: +40 800672524 |
Ireland GlaxoSmithKline (Ireland) Ltd Tel: + 353 (0)1 495 5000 | Slovenija GlaxoSmithKline Biologicals SA Tel: + 386 80688869 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika GlaxoSmithKline Biologicals SA Tel: + 421 800500589 |
Italia GlaxoSmithKline S.p.A. Tel: + 39 (0)45 774 1111 | Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 10 30 30 30 |
Κύπρος GlaxoSmithKline Biologicals SA Τηλ: + 357 80070017 | Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 info.produkt@gsk.com |
Latvija GlaxoSmithKline Biologicals SA Tel: + 371 80205045 | United Kingdom (Northern Ireland) GlaxoSmithKline Biologicals SA Tel: +44 (0)800 221 441 customercontactuk@gsk.com |
Date of last revision of this leaflet:04/2023
Other sources of information
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu, and on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).
-------------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
During storage of the vaccine, a fine white deposit and a clear supernatant may be observed.
Before administration, the vaccine should be shaken well to obtain a slightly opaque white suspension.
The vaccine should be inspected visually before and after resuspension for any foreign particles and/or changes in physical appearance. The vaccine should not be used if there has been a change in the appearance of the vaccine.
Disposal of unused medicinal products and all materials that have come into contact with them should be done in accordance with local regulations.
Fendrix should not be administered to subjects with hypersensitivity to the active substance or to any of the excipients.
Fendrix should not be administered to subjects with hypersensitivity after a previous administration of other hepatitis B vaccines.
Fendrix should not be administered to subjects with acute severe febrile illnesses. The presence of a minor infection, such as a cold, is not a contraindication for vaccination.
Fendrix should be injected intramuscularly in the deltoid region.
Intramuscular administration in the gluteal muscle should be avoided as it may lead to a suboptimal immune response to the vaccine.
Fendrix should not be administered intradermally or intravenously under any circumstances.
Due to the fact that pre-dialysis and dialysis patients are particularly exposed to HBV and have a higher risk of being chronically infected, a preventive attitude should be considered, i.e., a booster dose should be administered to ensure a protective level of antibodies based on local recommendations and guidelines.
Adequate medical treatment should be available at all times in the event of an anaphylactic reaction following administration of the vaccine.
Instructions for the pre-filled syringe
Hold the syringe by the body, not by the plunger. Unscrew the syringe cap by turning it counterclockwise. | |
To insert the needle, connect the base to the Luer-Lock adapter and turn it a quarter turn clockwise until it clicks. Do not pull the plunger out of the syringe body. If this happens, do not administer the vaccine. |
Waste disposal
Disposal of unused medicinal products and all materials that have come into contact with them should be done in accordance with local regulations.